University of Bergen (UiB)


University of Bergen

Department of Biomedicine
Jonas Lies vei 91
5009 Bergen. Norway

University of Bergen
Department of Biomedicine


Jan Haavik
Prof. Jan Haavik, MD PhD

Phone:+47 5558 6432
Fax:+47 5558 6360

Send message


The University of Bergen (UiB) is a young, modern university with about 14 300 students and 3,500 faculty and staff. Six faculties cover most of the traditional university disciplines. Within the faculties are included 60 different specialized departments, multi-disciplinary research centers and institutes.
Professor Jan Haavik leads a translational research centre (K.G. Jebsen Centre for Neuropsychiatric Disorders) that has an extensive experience from studies on ADHD and related psychiatric and somatic conditions. Using national registries and large clinical cohorts they have demonstrated patterns of comorbidity in psychiatric and somatic diseases. They have also contributed to multi-centre genomic studies that have shown overlapping genetic susceptibility for some of these conditions. The groups of Jan Haavik and Professor Aurora Martinez are examining effects of coding variants on protein functions in multiple model systems, including biophysical studies on pure proteins.
WP1: The University of Bergen hosts Medical birth registry of Norway, the world’s first national birth registry with data on 48 000 ADHD cases and 2 326 000 controls born 1967 – 2008. This information can be linked to many other national registries to study patterns of comorbidity.
WP 8 and Development of novel treatment approaches:
It is estimated that only 555 unique human genes are targeted by established pharmaceuticals, while approx. 475 potentially new targets are still in the clinical trial pipeline (Rask-Andersen). All approved drugs for ADHD were developed decades ago and all target a few targets within monoamine neurotransmission. In WP8, we will use genetic data generated in WP2-4 and existing data to identify new drugable targets through bioinformatics, and initiate in silico and in vitro screening for pharmaco-chaperones rescuing protein misfolding through disease-causing mutations. Our experimental pipeline for this has been validated and resulting pharmacological leads are already successfully applied in models of neurological disorders, offering opportunities for “personalized medicine”. Repurposing of existing pharmacological compounds is particularly attractive for treatment of comorbid conditions.